The company ended the quarter with $1.9 billion in cash, cash equivalents, and marketable securities. CRISPR is working to expand Casgevy in SCD and TDT. For example, they have completed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback